Evaluation of Lens culinaris agglutinin-reactive α-fetoprotein for diagnosis of malignant tumors
Abstract Background: To assess the potential of AFP-L3% for the utility to diagnose malignant tumors.Methods: The AFP-L3 was concentrated from clinically-collected serum samples via the Hotgen Biotech glycosyl capture spin columns and then measured through the protein microarrays. The levels of AFP and AFP-L3 were detected by electrochemiluminescence immunoassay. In this retrospective study, 266 patients with the level of serum AFP-L3 over 1ng/ml were recruited from December 2014 through April 2019,Among them, 155 patients were clinically diagnosed/confirmed with malignant tumors, including 101 hepatocellular carcinomas, 47 stomach malignant tumors, and 7 other malignant tumors; and the rest of 111 patients were nomalignant tumors.Results: Patients with serum AFP-L3 level of greater than 1ng/ml were mainly detected in hepatic diseases, including hepatocellular carcinoma, cirrhosis and chronic hepatitis. In patients with no tumors, the levels of serum AFP-L3 over 1ng/ml were only observed in liver disease. The levels of AFP-L3 in blood were substantially greater in patients with HCC. Among the malignant tumor patients with the level of serum AFP-L3 over 1ng/ml, HCC accounted for 60%, gastric cancer for nearly 40%. The AFP, AFP-L3 and AFP-L3% in blood were increased significantly in patients with liver malignancy, chronic liver disease and cirrhosis. However, the elevation of AFP-L3 and AFP-L3% in the malignant cohort was more evident than that in the nonmalignant counterpart.Conclusions: AFP-L3 is likely to contribute to differential diagnosis of HCC as well as other hepatic diseases, AFP-L3% is a reliable indicator for diagnosing benign and malignant tumors..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
ResearchSquare.com - (2020) vom: 03. Sept. Zur Gesamtaufnahme - year:2020 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Qiong [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.21203/rs.3.rs-21727/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA034206833 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA034206833 | ||
| 003 | DE-627 | ||
| 005 | 20230429183946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220113s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-21727/v1 |2 doi | |
| 035 | |a (DE-627)XRA034206833 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-21727/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Lu, Qiong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Lens culinaris agglutinin-reactive α-fetoprotein for diagnosis of malignant tumors |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background: To assess the potential of AFP-L3% for the utility to diagnose malignant tumors.Methods: The AFP-L3 was concentrated from clinically-collected serum samples via the Hotgen Biotech glycosyl capture spin columns and then measured through the protein microarrays. The levels of AFP and AFP-L3 were detected by electrochemiluminescence immunoassay. In this retrospective study, 266 patients with the level of serum AFP-L3 over 1ng/ml were recruited from December 2014 through April 2019,Among them, 155 patients were clinically diagnosed/confirmed with malignant tumors, including 101 hepatocellular carcinomas, 47 stomach malignant tumors, and 7 other malignant tumors; and the rest of 111 patients were nomalignant tumors.Results: Patients with serum AFP-L3 level of greater than 1ng/ml were mainly detected in hepatic diseases, including hepatocellular carcinoma, cirrhosis and chronic hepatitis. In patients with no tumors, the levels of serum AFP-L3 over 1ng/ml were only observed in liver disease. The levels of AFP-L3 in blood were substantially greater in patients with HCC. Among the malignant tumor patients with the level of serum AFP-L3 over 1ng/ml, HCC accounted for 60%, gastric cancer for nearly 40%. The AFP, AFP-L3 and AFP-L3% in blood were increased significantly in patients with liver malignancy, chronic liver disease and cirrhosis. However, the elevation of AFP-L3 and AFP-L3% in the malignant cohort was more evident than that in the nonmalignant counterpart.Conclusions: AFP-L3 is likely to contribute to differential diagnosis of HCC as well as other hepatic diseases, AFP-L3% is a reliable indicator for diagnosing benign and malignant tumors. | ||
| 700 | 1 | |a Xia, Jinxing |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Meijuan |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Zhongwei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2020) vom: 03. Sept. |
| 773 | 1 | 8 | |g year:2020 |g day:03 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-21727/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 03 |c 09 | ||
| 953 | |2 045F |a 570 | ||